 Connection
James Lambert to Signal Transduction
This is a "connection" page, showing publications James Lambert has written about Signal Transduction.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.216 |
|
|
|
-
Farrell KB, Das S, Nordeen SK, Lambert JR, Thamm DH. VDX-111 targets proliferative pathways in canine cancer cell lines. PLoS One. 2024; 19(5):e0303470.
Score: 0.085
-
Gari HH, DeGala GD, Ray R, Lucia MS, Lambert JR. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion. Cancer Lett. 2016 10 01; 380(2):505-512.
Score: 0.050
-
Whitson RJ, Lucia MS, Lambert JR. Growth differentiation factor-15 (GDF-15) suppresses in vitro angiogenesis through a novel interaction with connective tissue growth factor (CCN2). J Cell Biochem. 2013 Jun; 114(6):1424-33.
Score: 0.040
-
Persenaire C, Babbs B, Yamamoto TM, Nebbia M, Jordan KR, Adams S, Lambert JR, Bitler BG. VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. Mol Carcinog. 2024 Jul; 63(7):1248-1259.
Score: 0.021
-
Axlund SD, Lambert JR, Nordeen SK. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes. Mol Cancer Res. 2010 Dec; 8(12):1643-55.
Score: 0.008
-
Soto-Cerrato V, Vi?als F, Lambert JR, P?rez-Tom?s R. The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochem Pharmacol. 2007 Nov 01; 74(9):1340-9.
Score: 0.007
-
Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res. 2003 Sep 15; 63(18):5879-88.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|